• Renaissance Pharma Inc., of Newtown, Pa., acquired the U.S. rights to manufacture, market and sell Denavir (1 percent penciclovir cream) from investment funds managed by Deerfield Management Co. and New American Therapeutics Inc., of Cranford, N.J.